Get the Stockscreener App
0.1109
20.80%
0.0186
Conduit Pharmaceuticals Inc stock is traded at $0.1109, with a volume of 489.76M.
It is up +20.80% in the last 24 hours and up +4.99% over the past month.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
See More
Previous Close:
$0.0923
Open:
$0.14465
24h Volume:
489.76M
Relative Volume:
25.13
Market Cap:
$9.73M
Revenue:
-
Net Income/Loss:
$-4.21M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+18.74%
1M Performance:
+4.99%
6M Performance:
-96.28%
1Y Performance:
-91.42%
1-Day Range:
$0.1076
$0.1579
1-Week Range:
$0.0826
$0.1579
52-Week Range:
$0.0789
$7.83
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Name
Conduit Pharmaceuticals Inc
Sector
Industry
Phone
(646) 491 9132
Address
4851 TAMIAMI TRAIL NORTH, NAPLES
Compare CDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CDT | 0.1109 | 9.73M | 0 | -4.21M | 0 | 0.00 |
| VRTX | 447.42 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.15 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.88 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Conduit Pharmaceuticals Inc Stock (CDT) Latest News
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders - The Manila Times
Conduit Pharma Secures Key Patent for Autoimmune Drug AZD1656 in Major Japan Market | CDT Stock News - StockTitan
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - The Malaysian Reserve
Conduit Pharmaceuticals reshuffles board and amends bylaws - Investing.com
Conduit Pharmaceuticals reshuffles board and amends bylaws By Investing.com - Investing.com UK
Conduit Pharmaceuticals Announces Leadership Changes and Bylaws Update - TipRanks
Conduit Pharmaceuticals Strengthens Board with 30-Year Investment Banking Veteran Simon Fry | CDT Stock News - StockTitan
Conduit Pharmaceuticals announces restatement of financials - Investing.com
Remitly Global Inc (NASDAQ: RELY) Is The Number One Stock Currently Moving. - Stocks Register
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Conduit Pharmaceuticals announces new addition to autoimmune pipeline - Yahoo Finance
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline - StockTitan
Conduit Pharmaceuticals Opens New Lab Space In Cambridge, UK - Contract Pharma
Conduit Pharmaceuticals secures $1.2 million in funding - Investing.com India
Conduit Pharmaceuticals secures $1.2 million in funding By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals announces debt restructuring and additional notes - MSN
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - The Manila Times
LeMaitre to Participate at Upcoming Investor Conferences in November - The Manila Times
Conduit Pharmaceuticals Secures Funding and Modifies Debt Agreements - TipRanks
Prologis Inc (NYSE: PLD): Forecast Strong In 2024, Up 18.49% - Stocks Register
Where Do Analysts Think The Conduit Pharmaceuticals Inc (NASDAQ: CDT) Is Going - Stocks Register
Presidio Property Trust Provides Update on Model Home Activity in Q3 2024 - The Manila Times
Conduit Pharmaceuticals announces debt restructuring By Investing.com - Investing.com Australia
Conduit Pharmaceuticals announces debt restructuring - Investing.com India
CDT Stock on the Rise: A Promising Investment - The InvestChronicle
Conduit Pharmaceuticals Inc [CDT] Insider Nirland Ltd sells 1,500,000 Shares – Insider Selling Alert - Knox Daily
Investing in Capricor Therapeutics Inc (CAPR): What You Must Know - Knox Daily
A stock that deserves closer examination: Conduit Pharmaceuticals Inc (CDT) - US Post News
CDT’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Selling Buzz: Conduit Pharmaceuticals Inc [CDT] 10% Owner Nirland Ltd sells 1,500,000 shares of the company - Knox Daily
Astrazeneca PLC Reports 9.9% Passive Stake In Conduit Pharmaceuticals Inc As Of August 7SEC Filing - XM
There is no way Conduit Pharmaceuticals Inc (CDT) can keep these numbers up - SETE News
Conduit Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
Ltd Nirland Sells 939,009 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Stock - Defense World
Conduit Pharmaceuticals insiders sell shares worth over $393k By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals insiders sell shares worth over $393k - Investing.com
Market cap of Conduit Pharmaceuticals Inc [CDT] reaches 9.50M – now what? - The DBT News
Examining Conduit Pharmaceuticals Inc (CDT) more closely is necessary - US Post News
Balance Sheet Dive: Conduit Pharmaceuticals Inc (CDT)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Conduit Pharmaceuticals Inc [CDT] Records 50-Day SMA of $0.1531 - Knox Daily
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Conduit Pharmaceuticals executives sell shares worth over $297k By Investing.com - Investing.com Canada
Conduit Pharmaceuticals executives sell shares worth over $297k - Investing.com
Insider Selling: Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Major Shareholder Sells 1,016,823 Shares of Stock - Defense World
Conduit Pharmaceuticals Inc (CDT) expanding its growth trajectory ahead - SETE News
Market cap of Conduit Pharmaceuticals Inc [CDT] reaches 10.18M – now what? - The DBT News
Conduit Pharmaceuticals Inc [CDT] Insider Regan Andrew sells 10,244,392 Shares – Insider Selling Alert - Knox Daily
CDT stock plunges to 52-week low, touches $0.11 amid market challenges - Investing.com Canada
Presidio Property Trust Announces Series D Preferred Stock Cash Dividend - The Manila Times
In the Green: Conduit Pharmaceuticals Inc (CDT) Closes at 0.13, Up/Down -2.64 from Previous Day - The Dwinnex
Conduit Pharmaceuticals Inc Stock (CDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):